The aim of the present study was to examine the effect of new phosphodiesterase type 5 inhibitor vardenafil on endothelial function of cavernous and brachial arteries in healthy men and in patients with different forms of erectile dysfunction (ED). This prospective, double-blind, placebocontrolled study was performed on 135 men with ED and 30 healthy controls. Complex evaluation was performed in all patients with ED. All participants also underwent our modification of ultrasound (US) assessment of postocclusive changes in the diameter of cavernosal arteries and endothelium-dependent flow-mediated dilation (FMD) of the brachial artery before and 1 h after administration of 20 mg of vardenafil or placebo. After study drug administration, PICAD and FMD significantly increased in patients receiving vardenafil (Po0.001) but not in patients receiving placebo. Increase in PICAD values was significantly greater in patients with arteriogenic ED compared with patients with organic nonarterial ED (P ¼ 0.007), psychogenic ED (Po0.001) and controls (P ¼ 0.001). The most prominent increase in brachial artery FMD values were found in patients with arteriogenic ED, although statistically significant differences were present only between patients with arteriogenic ED and control group (P ¼ 0.035). We have found a moderate negative correlation between initial PICAD and its increase after vardenafil and between pretreatment flow-mediated vasodilation of brachial arteries and its increase after vardenafil administration (r ¼ À0.57 and À0.55, respectively). These findings suggest that the use of vardenafil restores impaired endothelial function of cavernous and brachial arteries.
Introduction
Erectile dysfunction (ED) is defined as the consistent inability to obtain or maintain an erection sufficient for satisfactory sexual intercourse. 1 It is now well recognized that ED is associated with risk factors for cardiovascular disease including lipid abnormalities, hypertension, diabetes, smoking, obesity and lack of physical activity. [2] [3] [4] [5] Loss of the functional integrity of the endothelium and subsequent endothelial dysfunction plays an integral role in the occurrence of ED in this cohort of men. 6 Penile erection is the end result of smooth muscle relaxation in the penis. Principal mechanism for producing erectile tissue relaxation is nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway. NO is released by efferent neuronal cells and endothelial cells in response to erectogenic stimuli and endothelium has a fundamental role in the process of erection. 7 Furthermore, NO is the key endothelium-derived relaxing factor that plays a pivotal role in the maintenance of vascular tone and reactivity. Endothelial dysfunction is defined as an imbalance in which the effects of vasoconstrictors outweigh the effects of vasodilators and generally results from decreased NO bioactivity. In endothelial system of penis, it causes impaired vascular reactivity, impaired relaxation of smooth muscle cells and finally ED. 6 NO exerts many of its effects by activation of soluble guanylate cyclase, leading to increased production of cGMP, which results in lower intracellular calcium levels and, therefore, relaxation of smooth muscle cells. 7 Phosphodiesterase type 5 (PDE-5) catalyzes the degradation of cGMP, thus PDE-5 inhibitors increase concentration of this second messenger and promote corporeal smooth muscle relaxation. 8 Generally speaking, PDE-5 inhibitors amplify effects of endogenous NO. In the case of endothelium-derived NO, it could mean improvement of endothelial function.
To our knowledge, no information on influence of PDE-5 inhibition on endothelial function of cavernous arteries in vivo has been reported probably owing to the absence until recently of methods of its evaluation.
Virag was first to investigate the possibility of evaluating endothelial function of cavernous arteries in vivo.
9,10 Recently, we have described our modification of this method, which involves ultrasound (US) assessment of postocclusive changes in the diameter of cavernosal arteries.
11 Similar method is widely used for the evaluation of endothelial function of other peripheral vessels including the brachial, carotid, superficial femoral and radial arteries. 12 Several authors investigated effects of PDE-5 inhibitor sildenafil on brachial artery endothelium-dependent flow-mediated dilation (FMD) in patients with chronic heart failure, diabetes mellitus and in smokers. [12] [13] [14] [15] [16] All these studies have demonstrated that inhibition of PDE-5 by sildenafil resulted in increases in endothelium-dependent FMD that testified improvement of endothelial function. Similar findings were reported in men with increased cardiovascular risk after chronic treatment with another PDE-5 inhibitor, tadalafil. 17 On the other hand, Dishy et al. 18, 19 failed to show any improvements in endothelium-dependent vasodilation in healthy men and chronic smokers after administration of sildenafil that cast doubt on the effects of PDE-5 inhibition on endothelial function.
It should be noted that in all aforementioned studies etiology of ED was left out of account. However, we and others have shown that patients with arteriogenic ED have abnormal endotheliumdependent vasodilation of both brachial and cavernous arteries. 11, 20 Differences in baseline status of endothelial function could result in differences in pharmacological effects.
The aim of the present study was to examine the effect of new PDE-5 inhibitor vardenafil on endothelial function of cavernous and brachial arteries in healthy men and in patients with different forms of ED.
Materials and methods
This was a prospective, double-blind, placebocontrolled study.
The study was performed on 135 men (mean age 51.0714.2 years, range 21-80 years) presenting to our department complaining of ED for at least 6 months (mean duration 1.872.0 years, range 0.5-7 years) and 30 healthy volunteers (mean age 52.1711.6 years, range 18-73 years) without sexual problems, which formed the control group. The absence of any sexual problems in the patients included in the control group was confirmed by history and erectile function domain of the International Index of Erectile Function (IIEF) scores (greater than 26). All men had a stable couple relationship, were treatment naïve and were not receiving nitrates.
Ethical review board approved the study protocol and patients provided written informed consent for study participation.
All patients with ED underwent complex evaluation, which included detailed sexual, medical and psychological history, IIEF questionnaire, physical and neurological examination, laboratory tests (fasting glucose, lipid profile, testosterone, luteinizing hormone, follicle-stimulating hormone and prolactin), Doppler US of the penile arteries after intracavernosal injection of prostaglandin E 1 and cavernosal EMG.
Patients with ED and controls were randomly assigned to one of two treatment groups. One group received vardenafil 20 mg and the other received placebo. Drugs were provided by the pharmacy of our institution.
All men included in the study underwent our modification of US assessment of postocclusive changes in the diameter of cavernosal arteries (the so-called penile NO release test) before and 1 h after oral ingestion of vardenafil (20 mg) or placebo.
Technique of US assessment of postocclusive changes in the diameter of cavernosal arteries: With the patient supine and penis slightly stretched to the abdomen, the transducer was placed on the ventral penile surface and the cavernosal arteries were examined about 2.5-3 cm distally of the penoscrotal junction. Diameters of both arteries were recorded. The place of examination was marked. After measurement of blood pressure, the special sphygmomanometric cuff (width 2 cm) was placed at the base of penis. Thereafter, arterial occlusion was created by cuff inflation to at least 10 mm Hg above systolic blood pressure. We confirmed the absence of blood flow below the cuff by color Doppler examination. In 5 min, the cuff was deflated and examination of cavernosal arteries was repeated at the same level as earlier (i.e. below the cuff location) 30-120 s after cessation of occlusion, three diameter measurements were averaged. As the main outcome measure, we took the percent of increase of the cavernosal arteries diameter, which was calculated using the following formula:
where PICAD is the percent of increase of cavernosal arteries diameter; Dbo is the mean diameter of both cavernosal arteries before occlusion; and Dao Effect of vardenafil on endothelial function E Mazo et al is the mean diameter of both cavernosal arteries after occlusion.
Endothelium-dependent FMD of the brachial artery in response to transient arterial occlusion also was determined in all patients before and 1 h after administration of 20 mg of vardenafil or placebo. This technique was described elsewhere. 18 We occluded the artery for 5 min and measured brachial artery diameter at end-diastole 30-90 s after the release of the occluding cuff; five diameter measurements were averaged. FMD was expressed as the percent change from the diameter before occlusion.
Technos (Esaote, Italy) scanner and LA 523 10-5 transducer (7.5 MHz) were used for obtaining realtime images and determination the diameter of cavernosal and brachial arteries. Studies were conducted in quiet and temperature-controlled room (22-231C). In order to exclude possible factors, affecting flow-mediated vascular reactivity subjects fasted for at least 8-12 h before the study and all vasoactive medications were withheld for at least four half-lives. The studies were performed at two sessions, separated by a minimum 3-day interval. All studies were performed by the same investigator.
Mean values of PICAD and FMD of brachial artery before and 1 h after ingestion of vardenafil and placebo were calculated for the control group and patients with ED. In the latter group, we compared PICAD and FMD of brachial arteries between groups of patients with different forms of ED. We also investigated the correlation between initial PICAD and FMD values and their changes after administration of vardenafil or placebo.
Values are expressed as mean7s.d. or percentages when appropriate. Statistical analysis was performed using Student's t-values, Pearson's w 2 test, Wilcoxon's signed-rank test and Spearman's correlation analysis as appropriate. Differences in FMD before and after study drug were analyzed with a repeated measures analysis of variance (ANOVA) model with one within-group factor (before/after study drug) and one between-group factor (treatment assignment), and expanded repeated measures ANOVA model was also used to determine differences in response to vardenafil. Computer software Statistica 6.0 for Windows was used for all statistical analysis with Po0.05 considered statistically significant.
Results
The clinical characteristics of two treatment groups (vardenafil and placebo) are presented in Table 1 . Baseline demographics and disease characteristics were similar between patients randomized to vardenafil and placebo.
The classification of ED was based on history and laboratory and instrumental investigations described earlier. Dividing men with organic ED into patients without alterations in arterial circulation in cavernous bodies according to Doppler study (neurogenic and venoocclusive ED) (organic nonarterial ED group) and with arteriogenic ED is accounted for by the results of our previous studies, which showed that alterations in cavernous arteries endothelial function were present specifically in patients with arteriogenic ED, whereas they were absent in other forms of organic ED. There were no patients with hormonal ED in our sample.
Before study drug administration, PICAD and FMD values did not significantly differ among two treatment groups. After study drug administration, PICAD and FMD significantly increased in patients receiving vardenafil (Po0.001) but not in patients receiving placebo (Table 2) . Changes in FMD and PICAD compared to baseline after vardenafil administration were significantly greater than after placebo Table 3 shows PICAD and FMD values in different groups of patients with ED and controls before and after vardenafil administration. In patients with arteriogenic ED, both indexes were significantly less than in patients with other forms with ED and controls (Po0.001), whereas there were no differences between groups of patients with other forms of ED and control group. Vardenafil administration caused significant increases in PICAD and FMD values in all groups. Increase in PICAD values was significantly greater in patients with arteriogenic ED compared with patients with organic nonarterial ED (P ¼ 0.007), psychogenic ED (Po0.001) and controls (P ¼ 0.001) (Figure 1) . The most prominent increase in brachial artery FMD values were found in patients with arteriogenic ED (Figure 2) , although statistically significant differences were present only between patients with arteriogenic ED and control group (P ¼ 0.035).
We have found a moderate negative correlation between initial PICAD and its increase after vardenafil ( Figure 3 ) and between pretreatment flowmediated vasodilation of brachial arteries and its increase after vardenafil administration (Figure 4 ) (r ¼ À0.57 and À0.55, respectively).
Discussion
The principal finding of this study is that administration of 20 mg of vardenafil significantly improves endothelium-dependent vasodilation of cavernous and brachial arteries. This improvement was observed across nearly all studied men. The study also demonstrated that the extent of improvement is dependent on the initial status of the vessels endothelial function. The effect of vardenafil was found to be the most pronounced in patients with arteriogenic ED, in which baseline values of 21 who reported greater improvements of endothelium-dependent coronary vascular responses and vasomotion in patients with coronary artery disease and severe endothelial dysfunction compared to healthy controls.
We suggest that this regularity accounts for the controversies on the results of previous studies of the effects of the PDE-5 inhibitor sildenafil on endothelial function. In one of the studies that failed to show improvements in endothelial function after administration of sildenafil, the study sample consisted of healthy men. 18 As for the other study, the reason of the discrepancy could be the small number of studied chronic smokers (n ¼ 9). 19 Improvement of endothelial function after administration of PDE-5 inhibitors is caused by amplification of NO-mediated vasodilation owing to the inhibition of cGMP degradation in the smooth muscle cells. We hypothesize that in the absence of alterations of endothelial function the action of endothelium-derived NO released during reactive hyperemia leads to close to maximal vasodilation and increase in intracellular cGMP levels cannot markedly affect it. In the case of endothelial dysfunction, enhanced smooth muscle concentration of cGMP produces significantly greater vasodilation as a consequence of activation of previously latent mechanisms.
We have assessed for the first time effects of PDE-5 inhibitor vardenafil on endothelial function of cavernosal arteries in vivo. We used the method of US assessment of postocclusive changes in the diameter of cavernosal arteries, which was shown to be reliable and highly informative tool for evaluation of the penile arterial circulation. 11 We believe that this method in future would be useful in investigations of other aspects of cavernosal arteries' endothelial function, which plays a key role in the pathogenesis of arteriogenic ED.
Conclusion
The present study demonstrates that effect of vardenafil on endothelial function depends on its initial state. The most prominent improvement of endothelium-dependent vasodilation of cavernous and brachial arteries was observed in men with endothelial dysfunction of the vessels. These findings suggest that the use of vardenafil restores impaired endothelial function of cavernous and brachial arteries. Figure 4 Correlation between initial FMD of brachial arteries and its increase after vardenafil.
Effect of vardenafil on endothelial function
E Mazo et al
